Influenza Diagnostic Tests Market Size 2028 - By Application, Type & Manufacturers Across North America, Europe, APAC, South America, MEA Global Market Insights recently added a detailed market research study focused on the Global Influenza Diagnostic Tests Market across the global, regional and country level. The report provides 360° analysis of Influenza Diagnostic Tests Market from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Influenza Diagnostic Tests market and estimates the future trend of Global Influenza Diagnostic Tests industry on the basis of this detailed study. Browse key industry insights spread across 120 pages with 233 market data tables & 14 figures & charts from the report, “Influenza Diagnostic Tests Market Analysis By Test Type (Traditional Diagnostic Test {Rapid Influenza Diagnostic Test (RIDT), Direct Fluorescent Antibody Test (DFAT), Viral Culture, Serological Assay}, Molecular Diagnostic Assay {RTPCR, Loop-mediated Isothermal Amplification-based Assay (LAMP), Nucleic Acid Sequencebased Amplification Test (NASBAT), Simple Amplification-based Assay (SAMBA)}), End-use (Hospitals, Diagnostics Centers, Research Laboratories), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028” in detail along with the table of contents: https://www.gminsights.com/industry-analysis/influenza-diagnostic-tests-market In addition, the World Health Organization claims that the annual influenza epidemics during winter and autumn affect nearly 5 to 15% of the population in the Northern hemisphere. Increase in such cases would foster the need for the development of diagnostic tests for influenza. The overall influenza diagnostic tests market has been classified on the basis of end-use, test type, and regional landscape. Considering the test type, the market is segmented into traditional diagnostic test and molecular diagnostic assay. Out of these two, the industry would observe substantial growth from the molecular diagnostic assay segment, which was valued at more than $668 million. Going further, industry analysts expect the segment to expand at a CAGR of 8.5% through the analysis timeline. This can be credited to the test's capability to deliver effective and accurate testing, which is in line with its ability to offer improved efficacy, resulting in enhanced outcomes.
© 2022 All Rights Reserved
www.gminsights.com